The stock of PAREXEL International Corporation (NASDAQ:PRXL) hit a new 52-week low and has $53.20 target or 7.00% below today’s $57.20 share price. The 8 months bearish chart indicates high risk for the $3.01 billion company. The 1-year low was reported on Nov, 7 by Barchart.com. If the $53.20 price target is reached, the company will be worth $210.70 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 693,525 shares traded hands or 32.59% up from the average. PAREXEL International Corporation (NASDAQ:PRXL) has declined 12.26% since April 5, 2016 and is downtrending. It has underperformed by 14.22% the S&P500.
PAREXEL International Corporation (NASDAQ:PRXL) Ratings Coverage
Out of 9 analysts covering Parexel International (NASDAQ:PRXL), 3 rate it a “Buy”, 1 “Sell”, while 5 “Hold”. This means 33% are positive. Parexel International has been the topic of 18 analyst reports since August 7, 2015 according to StockzIntelligence Inc. Evercore upgraded the shares of PRXL in a report on Wednesday, January 6 to “Buy” rating. Credit Suisse reinitiated PAREXEL International Corporation (NASDAQ:PRXL) rating on Friday, August 14. Credit Suisse has “Outperform” rating and $75 price target. Deutsche Bank maintained it with “Hold” rating and $65 target price in Friday, October 28 report. The company was initiated on Tuesday, June 21 by Credit Suisse. The firm earned “Neutral” rating on Tuesday, September 6 by UBS. On Friday, August 7 the stock rating was maintained by Deutsche Bank with “Hold”. The firm has “Hold” rating given on Friday, August 7 by Deutsche Bank. The firm has “Underperform” rating given on Monday, April 11 by Avondale. The firm has “Outperform” rating by Credit Suisse given on Friday, August 7. The firm has “Neutral” rating given on Thursday, October 27 by Robert W. Baird.
According to Zacks Investment Research, “Parexel International Corporation is one of the largest biopharmaceutical outsourcing organizations in the world, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. With a commitment to providing solutions that expedite time-to-market and peak market penetration, PAREXEL has developed significant expertise in clinical trials management, data management, biostatistical analysis, medical marketing, clinical pharmacology, regulatory and medical consulting, industry training and publishing and other drug development consulting services. Its information technology subsidiary, Perceptive Informatics, Inc., develops and offers a portfolio of innovative technology-based products and services that facilitate clinical drug development and are designed to decrease time to peak sales.”
Insitutional Activity: The institutional sentiment increased to 1.16 in 2016 Q2. Its up 0.05, from 1.11 in 2016Q1. The ratio improved, as 31 funds sold all PAREXEL International Corporation shares owned while 96 reduced positions. 45 funds bought stakes while 102 increased positions. They now own 46.71 million shares or 2.30% less from 47.81 million shares in 2016Q1.
Fmr Limited Liability Corp accumulated 0.01% or 1.00 million shares. State Treasurer State Of Michigan accumulated 21,200 shares or 0.01% of the stock. Eaton Vance holds 0% or 4,200 shares in its portfolio. Peak6 Investments Lp has 0.01% invested in the company for 13,278 shares. Intrust Comml Bank Na has invested 0.25% of its portfolio in PAREXEL International Corporation (NASDAQ:PRXL). Glenmede Trust Company Na has 0.02% invested in the company for 46,530 shares. Hsbc Hldg Public Limited Com accumulated 0% or 6,202 shares. Bnp Paribas Arbitrage Sa reported 23,749 shares or 0.01% of all its holdings. Janney Montgomery Scott Ltd Liability reported 12,030 shares or 0.01% of all its holdings. Azimuth Cap Management Ltd Liability Corporation holds 0.09% of its portfolio in PAREXEL International Corporation (NASDAQ:PRXL) for 15,175 shares. New York State Teachers Retirement Sys last reported 101,803 shares in the company. Assetmark Inc accumulated 0% or 5 shares. New York State Common Retirement Fund last reported 72,355 shares in the company. Trexquant Invest Ltd Partnership reported 13,005 shares or 0.11% of all its holdings. The Massachusetts-based Congress Asset Mgmt Ma has invested 0.9% in PAREXEL International Corporation (NASDAQ:PRXL).
Insider Transactions: Since May 20, 2016, the stock had 0 insider buys, and 8 insider sales for $2.24 million net activity. The insider Saarony Gadi sold 2,500 shares worth $175,125. SCHNEIDER ULF I sold $465,000 worth of stock or 7,500 shares. Holdener Eduard E. sold 700 shares worth $44,086. Another trade for 2,500 shares valued at $171,600 was sold by Schultz Joshua. $180,120 worth of shares were sold by CALLOW A DANA JR on Monday, June 13.
More recent PAREXEL International Corporation (NASDAQ:PRXL) news were published by: Fool.com which released: “PAREXEL International Corporation’s Q1 Report Flops, Shares Sink As Much As 13%” on October 27, 2016. Also Bizjournals.com published the news titled: “Parexel loses $160M in value after disclosing possible embezzlement” on September 01, 2016. Prnewswire.com‘s news article titled: “SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …” with publication date: August 31, 2016 was also an interesting one.
PRXL Company Profile
PAREXEL International Corporation (PAREXEL), incorporated on January 3, 1983, is a biopharmaceutical outsourcing services company. The Firm provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology services and products to pharmaceutical, biotechnology and medical device industries. The Company’s divisions include Clinical Research Services (CRS), PAREXEL Consulting Services (PC) and PAREXEL Informatics (PI).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.